Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura E Johnson

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJordan T Becker, Brian M Olson, Laura E Johnson, et al.
Journal for Immunotherapy of Cancer|March 15, 2018
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccineEllen Wargowski, Laura E Johnson, Jens C Eickhoff, et al.
Hepatology (Baltimore, Md.)|September 30, 2008
The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in miceLaura E Johnson, Marc S Elias, David T Bolick, et al.
Plos One|June 2, 2017
Trends of vaccine-preventable diseases in Afghanistan from the Disease Early Warning System, 2009-2015Abram L Wagner, Mohammad Y Mubarak, Laura E Johnson, et al.
Anatomical Sciences Education|December 18, 2024
Human body donation programs best practices and recommended standards: A task force report from the American Association for AnatomyJoy Y Balta, Thomas H Champney, Christopher Ferrigno, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Vaccine|August 24, 2005
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)Laura E Johnson, Thomas P Frye, Alana R Arnot, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancerDouglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, et al.
Histology and Histopathology|September 10, 2013
Remote lung injury after experimental intestinal ischemia-reperfusion in horsesJulia B Montgomery, Brie Hamblin, Sarabjeet Singh Suri, et al.
Circulation Research|December 25, 2008
G2A deficiency in mice promotes macrophage activation and atherosclerosisDavid T Bolick, Marcus D Skaflen, Laura E Johnson, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJordan T Becker, Brian M Olson, Laura E Johnson, et al.
Journal for Immunotherapy of Cancer|March 15, 2018
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccineEllen Wargowski, Laura E Johnson, Jens C Eickhoff, et al.
Hepatology (Baltimore, Md.)|September 30, 2008
The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in miceLaura E Johnson, Marc S Elias, David T Bolick, et al.
Plos One|June 2, 2017
Trends of vaccine-preventable diseases in Afghanistan from the Disease Early Warning System, 2009-2015Abram L Wagner, Mohammad Y Mubarak, Laura E Johnson, et al.
Anatomical Sciences Education|December 18, 2024
Human body donation programs best practices and recommended standards: A task force report from the American Association for AnatomyJoy Y Balta, Thomas H Champney, Christopher Ferrigno, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Vaccine|August 24, 2005
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)Laura E Johnson, Thomas P Frye, Alana R Arnot, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancerDouglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, et al.
Histology and Histopathology|September 10, 2013
Remote lung injury after experimental intestinal ischemia-reperfusion in horsesJulia B Montgomery, Brie Hamblin, Sarabjeet Singh Suri, et al.
Circulation Research|December 25, 2008
G2A deficiency in mice promotes macrophage activation and atherosclerosisDavid T Bolick, Marcus D Skaflen, Laura E Johnson, et al.
Pageof 5